China-Coronavirus/Vaccine Trial

Preliminary results show China's COVID-19 vaccine candidate safe: The Lancet

  • English
  • Français
  • العربية
  • Pусский
  • Español
  • 日本語
  • Deutsch

Shotlist


Beijing, China - Oct 18, 2020 (CCTV - No access Chinese mainland)
1. Various of screenshot showing China's COVID-19 vaccine study in Lancet Infectious Diseases journal

FILE: China - Exact Date and Location Unknown (CCTV - No access Chinese mainland)
2. Various of medical workers conducting vaccine research in lab

FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
3. Various of researchers conducting experiment

FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
4. Various of vaccine production line

FILE: Wuhan City, Hubei Province, central China - March 16, 2020 (CCTV - No access Chinese mainland)
5. Bottles of vaccine

FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
6. Various of vaccine production line, researchers at production line

FILE: Wuhan City, Hubei Province, central China - May 2020 (CCTV - No access Chinese mainland)
7. Medical worker injecting vaccine
8. Various of volunteers receiving vaccine injections

Storyline


A COVID-19 vaccine candidate developed by China based on the inactivated whole SARS-CoV-2 virus is safe and elicits an antibody response, according to the findings from a small early-phase randomized clinical trial published Thursday in The Lancet Infectious Diseases journal.

The report said that from April 29 to July 30 this year, researchers from institutions including the Beijing Institute of Biological Products carried out related clinical trials in China, involving more than 600 healthy participants aged between 18 and 80 years old.

The latest study found that antibody responses were induced in all recipients within 42 days, and no serious adverse reaction occurred.

The research team stated that the trial at this stage is mainly to evaluate the immune response and vaccine safety, which has not been possible to confirm whether the vaccine is sufficient to protect people from SARS-CoV-2 infection. Further analysis and trials are needed to evaluate it. The preliminary trial result also provides very useful information for phase 3 clinical trials.

According to statistics from the World Health Organization, there are currently more than 40 COVID-19 vaccines in clinical trials worldwide, including vaccines with different types of technical routes, some of which have demonstrated safety in early clinical trials and can induce immune responses in human beings.

DOWNLOAD
  • ID : 8161993
  • Dateline : Oct 18, 2020/File
  • Location : China
  • Category : health
  • Duration : 1'06
  • Audio Language : Mute
  • Source : China Central Television (CCTV),China Global Television Network (CGTN)
  • Restrictions : No access Chinese mainland
  • Published : 2020-10-18 03:09
  • Last Modified : 2020-10-18 17:04:09
  • Version : 1
  • ID : 8161993
  • Dateline : 18 oct. 2020/Archives
  • Location : Chine
  • Category : health
  • Duration : 1'06
  • Audio Language : Muet
  • Source : China Central Television (CCTV),China Global Television Network (CGTN)
  • Restrictions : Pas d’accès dans la partie continentale de Chine
  • Published : 2020-10-18 16:42
  • Last Modified : 2020-10-18 17:04:09
  • Version : 1
  • ID : 8161993
  • Dateline : 18 أكتوبر 2020/ارشيف
  • Location : الصين
  • Category : health
  • Duration : 1'06
  • Audio Language : صامت
  • Source : China Central Television (CCTV),China Global Television Network (CGTN)
  • Restrictions : No access Chinese mainland
  • Published : 2020-10-18 15:30
  • Last Modified : 2020-10-18 17:04:09
  • Version : 1
  • ID : 8161993
  • Dateline : 18 окт 2020/Архив
  • Location : Китай
  • Category : health
  • Duration : 1'06
  • Audio Language : Немое
  • Source : China Central Television (CCTV)
  • Restrictions : Недоступно материковой части Китая
  • Published : 2020-10-18 15:35
  • Last Modified : 2020-10-18 17:04:09
  • Version : 1
  • ID : 8161993
  • Dateline : 18 oct. 2020/Archivo
  • Location : China
  • Category : health
  • Duration : 1'06
  • Audio Language : Mudo
  • Source : China Central Television (CCTV),China Global Television Network (CGTN)
  • Restrictions : No acceso a la parte continental de China
  • Published : 2020-10-18 16:46
  • Last Modified : 2020-10-18 17:04:09
  • Version : 1
  • ID : 8161993
  • Dateline : 2020年10月18日/資料
  • Category : health
  • Duration : 1'06
  • Audio Language : 音声なし
  • Source : China Central Television (CCTV)
  • Restrictions : 中国大陸での使用は不可
  • Published : 2020-10-18 15:53
  • Last Modified : 2020-10-18 17:04:09
  • Version : 1
  • ID : 8161993
  • Dateline : 18. Oktober 2020/ Archiv
  • Category : health
  • Duration : 1'06
  • Audio Language : Ohne Ton
  • Source : China Central Television (CCTV),China Global Television Network (CGTN)
  • Restrictions : Für das chinesische Festland nicht verfügbar
  • Published : 2020-10-18 15:55
  • Last Modified : 2020-10-18 17:04:09
  • Version : 1

China-Coronavirus/Vaccine Trial

Preliminary results show China's COVID-19 vaccine candidate safe: The Lancet

Dateline : Oct 18, 2020/File

Location : China

Duration : 1'06

  • English
  • Français
  • العربية
  • Pусский
  • Español
  • 日本語
  • Deutsch


Beijing, China - Oct 18, 2020 (CCTV - No access Chinese mainland)
1. Various of screenshot showing China's COVID-19 vaccine study in Lancet Infectious Diseases journal

FILE: China - Exact Date and Location Unknown (CCTV - No access Chinese mainland)
2. Various of medical workers conducting vaccine research in lab

FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
3. Various of researchers conducting experiment

FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
4. Various of vaccine production line

FILE: Wuhan City, Hubei Province, central China - March 16, 2020 (CCTV - No access Chinese mainland)
5. Bottles of vaccine

FILE: Beijing, China - Aug 21, 2020 (CGTN - No access Chinese mainland)
6. Various of vaccine production line, researchers at production line

FILE: Wuhan City, Hubei Province, central China - May 2020 (CCTV - No access Chinese mainland)
7. Medical worker injecting vaccine
8. Various of volunteers receiving vaccine injections


A COVID-19 vaccine candidate developed by China based on the inactivated whole SARS-CoV-2 virus is safe and elicits an antibody response, according to the findings from a small early-phase randomized clinical trial published Thursday in The Lancet Infectious Diseases journal.

The report said that from April 29 to July 30 this year, researchers from institutions including the Beijing Institute of Biological Products carried out related clinical trials in China, involving more than 600 healthy participants aged between 18 and 80 years old.

The latest study found that antibody responses were induced in all recipients within 42 days, and no serious adverse reaction occurred.

The research team stated that the trial at this stage is mainly to evaluate the immune response and vaccine safety, which has not been possible to confirm whether the vaccine is sufficient to protect people from SARS-CoV-2 infection. Further analysis and trials are needed to evaluate it. The preliminary trial result also provides very useful information for phase 3 clinical trials.

According to statistics from the World Health Organization, there are currently more than 40 COVID-19 vaccines in clinical trials worldwide, including vaccines with different types of technical routes, some of which have demonstrated safety in early clinical trials and can induce immune responses in human beings.

ID : 8161993

Published : 2020-10-18 03:09

Last Modified : 2020-10-18 17:04:09

Source : China Central Television (CCTV),China Global Television Network (CGTN)

Restrictions : No access Chinese mainland

More



Login
Username
Password
code
Sign In
OK